StreetInsider.com News Articles

Jyong Biotech presents BPH drug candidate at BIO 2026 convention

Thu, 02 Jul 2026 08:02:15 -0400

Jyong Biotech Ltd. (Nasdaq: MENS) participated in the BIO International Convention in San Diego, California, from June 22 to June 25, 2026, where the Taiwan-based biotechnology company presented its botanical drug candidate Botreso® to international pharmaceutical companies.

The company exhibited at the Taiwan Pavilion and held discussions with pharmaceutical companies, investment institutions, and industry partners. Jyong Biotech states it has participated in the BIO International Convention for over a decade.

Botreso®, which targets benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS), has undergone four Phase III clinical trials across the United States and Taiwan. As of the press release date,

Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention

Thu, 02 Jul 2026 08:00:00 -0400

New Taipei City, Taiwan, July 02, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today announced its participation in the BIO International Convention (BIO 2026), held in San Diego, California, from June 22 to June 25, 2026. Having participated in the BIO International Convention for over a decade without missing a single year, Jyong Biotech once again exhibited at the Taiwan Pavilion. The Company conducted in-depth discussions with global pharmaceutical companies, investment institutions, and industry partners and

Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention

Thu, 02 Jul 2026 08:00:00 -0400

Jyong Biotech CEO details FDA pathway for botanical BPH drug

Fri, 29 May 2026 08:02:13 -0400

Jyong Biotech Ltd. (NASDAQ: MENS) outlined its regulatory strategy and development timeline for its botanical drug candidate Botreso®, designed to treat benign prostatic hyperplasia (BPH), according to a company statement based on a recent CEO interview.

Chief Executive Officer Fu-Feng Kuo said the Taiwan-based biotechnology company plans to submit a combined New Drug Application (NDA) to the FDA between 2029 and 2030. The submission will require completion of a US pharmacokinetic study and a Phase III trial using a second active pharmaceutical ingredient source, designated API-2.

Jyong Biotech has completed two pivotal studies and two one-year open-label extension studies for Botreso® across

Jyong Biotech CEO details FDA pathway for botanical BPH drug

Fri, 29 May 2026 08:02:13 -0400

Jyong Biotech has completed two pivotal studies and two one-year open-label extension studies for Botreso® across

Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview

Fri, 29 May 2026 08:00:00 -0400

New Taipei City, Taiwan, May 29, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today highlighted a strategic vision detailed by its founder and chief executive officer, Ms. Fu-Feng Kuo, in a recently published live interview with PharmaBoardroom, a UK-based platform providing global intelligence for the healthcare and life sciences industries.

In the interview, CEO Kuo described how Jyong Biotech has built its scientific foundation through a hybrid operating model, pairing its Taiwanese R&D subsidiary,

Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview

Fri, 29 May 2026 08:00:00 -0400

In the interview, CEO Kuo described how Jyong Biotech has built its scientific foundation through a hybrid operating model, pairing its Taiwanese R&D subsidiary,

Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025

Fri, 15 May 2026 08:30:00 -0400

New Taipei City, Taiwan, May 15, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission ("SEC") on May 14, 2026.

The annual report can be accessed on the Company's investor relations website at https://jyongir.com/ as well as the SEC's website at http://www.sec.gov.

The

Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025

Fri, 15 May 2026 08:30:00 -0400

The annual report can be accessed on the Company's investor relations website at https://jyongir.com/ as well as the SEC's website at http://www.sec.gov.

The

Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025

Fri, 15 May 2026 08:30:00 -0400

The annual report can be accessed on the Company's investor relations website at https://jyongir.com/ as well as the SEC's website at http://www.sec.gov.

The

Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025

Fri, 15 May 2026 08:30:00 -0400

The annual report can be accessed on the Company's investor relations website at https://jyongir.com/ as well as the SEC's website at http://www.sec.gov.

The

Form 20-F Jyong Biotech Ltd. For: Dec 31

Fri, 15 May 2026 06:14:00 -0400

si-local-file:///var/storage/secattach/20260515/26498558.html

Form 20-F Jyong Biotech Ltd. For: Dec 31

Fri, 15 May 2026 06:14:00 -0400

si-local-file:///var/storage/secattach/20260515/26498558.html

Form NT 20-F Jyong Biotech Ltd. For: Dec 31

Wed, 29 Apr 2026 13:12:00 -0400

si-local-file:///var/storage/secattach/20260429/26392220.html

Form NT 20-F Jyong Biotech Ltd. For: Dec 31

Wed, 29 Apr 2026 13:12:00 -0400

si-local-file:///var/storage/secattach/20260429/26392220.html

Form NT 20-F Jyong Biotech Ltd. For: Dec 31

Wed, 29 Apr 2026 13:12:00 -0400

si-local-file:///var/storage/secattach/20260429/26392220.html

Jyong Biotech updates market strategy for botanical drug candidates

Tue, 28 Apr 2026 08:35:02 -0400

Jyong Biotech Ltd. (NASDAQ: MENS) announced it has updated market access strategies for its botanical drug candidates Botreso® and PCP following analysis of clinical trial data and competitive positioning.

The Taiwan-based biotechnology company reported that Botreso® has completed four Phase III clinical trials in the United States and Taiwan, while PCP finished its Phase II clinical trial. Both drugs target benign prostatic hyperplasia treatment.

According to the company, clinical trials showed no drug-related serious adverse events during a one-year period for Botreso® and a two-year period for PCP. The PCP Phase II trial involved 702 subjects across 20 hospitals in Taiwan with

Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio

Tue, 28 Apr 2026 08:30:00 -0400

New Taipei City, Taiwan, April 28, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today announced that it has advanced the market access strategies for its innovative plant-based drugs Botreso^® and PCP, after an analysis of their clinical efficacy and competitive advantages.

As previously announced, its first core product, Botreso^®, has completed four Phase III clinical trials (API-1) in the United States and Taiwan while its second core product, PCP, has successfully completed its Phase

Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio

Tue, 28 Apr 2026 08:30:00 -0400

Form SCHEDULE 13D Jyong Biotech Ltd. Filed by: Perfect Mind Co., Ltd

Fri, 24 Apr 2026 15:06:00 -0400

si-local-file:///var/storage/secattach/20260424/26365433.html

Form SCHEDULE 13D Jyong Biotech Ltd. Filed by: Perfect Mind Co., Ltd

Fri, 24 Apr 2026 15:06:00 -0400

si-local-file:///var/storage/secattach/20260424/26365433.html

Form SCHEDULE 13D Jyong Biotech Ltd. Filed by: Perfect Mind Co., Ltd

Fri, 24 Apr 2026 15:06:00 -0400

si-local-file:///var/storage/secattach/20260424/26365433.html

Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2

Fri, 27 Mar 2026 08:30:00 -0400

New Taipei City, Taiwan, March 27, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today provided an update on the plant-derived innovative drug MCS^®-2 of its multiple competitive advantages and its potential clinical benefits in the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).

Pioneering Plant-Based Therapeutics
Developed in Taiwan, MCS^®-2 is the world’s only oral botanical new drug to have completed a global Phase III clinical trial for benign prostatic hyperplasia

Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2

Fri, 27 Mar 2026 08:30:00 -0400

Pioneering Plant-Based Therapeutics
Developed in Taiwan, MCS^®-2 is the world’s only oral botanical new drug to have completed a global Phase III clinical trial for benign prostatic hyperplasia

Jyong Biotech completes phase II trial showing cancer prevention benefits

Thu, 12 Feb 2026 08:32:07 -0400

Jyong Biotech Ltd. (NASDAQ: MENS) announced completion of its Phase II clinical trial for MCS-8, which showed a 27.3% reduction in prostate cancer incidence compared to placebo in a study of over 700 high-risk subjects across 20 medical centers in Taiwan.

The randomized, placebo-controlled trial also demonstrated a 17.1% reduction in high-grade prostate cancer cases. Additional findings included a 35.2% reduction in positive biopsy cores and a 24.4% reduction in cancer-positive area within those cores.

The study revealed secondary metabolic benefits, with patients treated with MCS-8 showing statistically significant reductions in total cholesterol, triglycerides, and LDL levels, alongside increased HDL levels. The